{"nctId":"NCT01399619","briefTitle":"Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)","startDateStruct":{"date":"2011-09"},"conditions":["Hepatitis C, Chronic"],"count":310,"armGroups":[{"label":"BI201335 12W","type":"EXPERIMENTAL","interventionNames":["Drug: PegIFN/RBV","Drug: BI201335"]},{"label":"BI 201335 24W","type":"EXPERIMENTAL","interventionNames":["Drug: BI201335 24W","Drug: PegIFN/RBV"]},{"label":"BI 201335 24 W","type":"EXPERIMENTAL","interventionNames":["Drug: PegIFN/RBV","Drug: Bi 201335"]}],"interventions":[{"name":"PegIFN/RBV","otherNames":[]},{"name":"PegIFN/RBV","otherNames":[]},{"name":"BI201335","otherNames":[]},{"name":"BI201335 24W","otherNames":[]},{"name":"PegIFN/RBV","otherNames":[]},{"name":"Bi 201335","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Chronic hepatitis C (HCV) genotype 1 infection\n2. Chronic Human Immunodeficiency Virus (HIV) -1 infection\n3. HCV treatment naive or HCV treatment experienced but only relapsers\n4. Age 18 to 70 years\n5. Antiretroviral treatment naive or on stable Highly Active Antiretroviral Therapy (HAART)\n6. Karnofsky score \\>70\n7. HCV viral load \\>1.000 IU/mL\n\nExclusion criteria:\n\n1. HCV infection of mixed genotype (1/2, 1/3, 1/4)\n2. Evidence of acute or chronic liver due to chronic HCV infection\n3. Hepatitis B virus (HBV) infection with presence of HBs-Ag\n4. Active malignancy or history or malignancy within the last 5 years\n5. Received concomitant systemic antiviral (other than antiretroviral), hematopoietic growth factor or immunomodulatory treatment in 28 days prior enrolment.\n6. Decompensated liver disease,as evidenced by ascites, hepatic encephalopathy, esophageal variceal bleeding, and/or laboratory values that add up to \\>/= 7 points according tho the Child-Turcotte-Pugh classification\n7. Hemoglobin \\</=11g/dL for women and \\</= 12 g/dL for men\n8. Patients with stable cardiac disease and Hemoglobin \\<12g/dL\n9. Known hypersensitivity to any ingredient of the study drugs","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sustained Virological Response (SVR12)","description":"Percentage of participants with sustained Virological Response SVR12: Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) level \\<25 IU/mL, undetected 12 weeks after the planned end of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":null},{"groupId":"OG001","value":"78.6","spread":null},{"groupId":"OG002","value":"76.7","spread":null},{"groupId":"OG003","value":"72.4","spread":null},{"groupId":"OG004","value":"71.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Virological Response 24 Weeks Post Treatment (SVR24)","description":"Percentage of participants with virological response 24 weeks post treatment (SVR24): Plasma HCV RNA level\\<25IU/mL (undetected) 24 weeks after the planned end of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","spread":null},{"groupId":"OG001","value":"78.6","spread":null},{"groupId":"OG002","value":"74.4","spread":null},{"groupId":"OG003","value":"71.4","spread":null},{"groupId":"OG004","value":"70.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Success (ETS)","description":"Early Treatment Success (ETS): Plasma HCV RNA level\\<25 IU/mL (detected or undetected) at Week 4 and HCV RNA\\< 25 IU/mL, undetected at Week 8","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"73","spread":null},{"groupId":"OG003","value":"150","spread":null},{"groupId":"OG004","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"63","spread":null},{"groupId":"OG003","value":"127","spread":null},{"groupId":"OG004","value":"210","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at End of Treatment (EoT) When SVR12=Yes","description":"The number of participants with Alanine Aminotransferase (ALT) normalisation at End of Treatment (EoT) when SVR12=yes. BL stands for baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"134","spread":null},{"groupId":"OG004","value":"221","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"43","spread":null},{"groupId":"OG004","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"66","spread":null},{"groupId":"OG004","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at End of Treatment When SVR12=no","description":"The number of participants with Alanine Aminotransferase (ALT) normalisation: ALT in normal range at End of Treatment when SVR12=no. BL stands for baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"51","spread":null},{"groupId":"OG004","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"18","spread":null},{"groupId":"OG004","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"21","spread":null},{"groupId":"OG004","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at Post Treatment When SVR12=Yes","description":"The number of participants with ALT in normal range at post treatment (SVR12 Visit) when SVR12=yes. BL = baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"134","spread":null},{"groupId":"OG004","value":"221","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"45","spread":null},{"groupId":"OG004","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"81","spread":null},{"groupId":"OG004","value":"133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at Post Treatment When SVR12=no","description":"The number of participants with ALT in normal range at post treatment (SVR12 Visit) when SVR12=no. BL = baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"51","spread":null},{"groupId":"OG004","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"20","spread":null},{"groupId":"OG004","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at End of Treatment When SVR12=Yes","description":"The number of participants with Aspartate Aminotransferase (AST) normalisation at End of Treatment when SVR12=yes. BL = baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"134","spread":null},{"groupId":"OG004","value":"221","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"54","spread":null},{"groupId":"OG004","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"52","spread":null},{"groupId":"OG004","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at End of Treatment When SVR12=no","description":"The number of participants with Aspartate Aminotransferase (AST) normalisation at End of Treatment when SVR12=no. BL = baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"51","spread":null},{"groupId":"OG004","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"19","spread":null},{"groupId":"OG004","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"19","spread":null},{"groupId":"OG004","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at Post Treatment When SVR12=Yes","description":"The number of participants with AST in normal range at Post Treatment (SVR12 Visit) when SVR12=yes. BL = baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"134","spread":null},{"groupId":"OG004","value":"221","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"57","spread":null},{"groupId":"OG004","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"33","spread":null},{"groupId":"OG003","value":"69","spread":null},{"groupId":"OG004","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at Post Treatment When SVR12=no","description":"The number of participants with AST in normal range at Post Treatment (SVR12 Visit) when SVR12=no. BL = baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"51","spread":null},{"groupId":"OG004","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"13","spread":null},{"groupId":"OG004","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"20","spread":null},{"groupId":"OG004","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":123},"commonTop":["Nausea","Fatigue","Diarrhoea","Headache","Asthenia"]}}}